Chemomab Therapeutics (CMMB) Assets Average (2019 - 2025)

Chemomab Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $13.1 million for Q4 2025.

• Quarterly Assets Average fell 30.85% year-over-year to $13.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.1 million (down 30.85% YoY) and the FY2025 annual result came in at $15.4 million, down 21.32% from the prior year.
• Assets Average was $13.1 million for Q4 2025 at Chemomab Therapeutics, up from $11.7 million in the prior quarter.
• Across five years, Assets Average topped out at $69.0 million in Q3 2021 and bottomed at $11.7 million in Q3 2025.
• A 5-year average of $35.1 million and a median of $29.0 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2021 — Assets Average jumped 679.2% — and 2023, when it sank 51.15%.
• Chemomab Therapeutics' Assets Average stood at $65.9 million in 2021, then fell by 29.22% to $46.6 million in 2022, then plunged by 51.15% to $22.8 million in 2023, then decreased by 16.92% to $18.9 million in 2024, then tumbled by 30.85% to $13.1 million in 2025.
• Business Quant data shows CMMB's Assets Average at $13.1 million in Q4 2025, $11.7 million in Q3 2025, and $12.0 million in Q2 2025.